| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA722: Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement |
|
Medicine details |
|
| Medicine name | pemigatinib (Pemazyre®) |
| Formulation | 4.5 mg, 9 mg, 13.5 mg tablets |
| Reference number | 4438 |
| Indication | Treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy |
| Company | Incyte Biosciences |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 05/05/2021 |
| NICE guidance | |